Published in AIDS on July 31, 2009
Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic. PLoS Genet (2014) 0.91
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan. J Virol (2012) 0.88
Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology (2014) 0.79
Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. J Virol (2015) 0.75
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol (2009) 2.31
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS (2008) 2.25
Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS (2009) 2.07
Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS (2016) 1.97
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis (2004) 1.85
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS (2010) 1.81
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend (2005) 1.69
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis (2007) 1.61
Unravelling the impact of ethnicity on health in Europe: the HELIUS study. BMC Public Health (2013) 1.59
Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis (2014) 1.59
Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52
Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis (2014) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis (2009) 1.49
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (2003) 1.41
Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol (2005) 1.39
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. AIDS (2007) 1.38
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS (2011) 1.31
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS (2009) 1.27
Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. Sex Transm Dis (2008) 1.26
Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics (2006) 1.25
High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. Sex Transm Dis (2012) 1.25
Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol (2009) 1.24
Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure. AIDS Res Hum Retroviruses (2002) 1.23
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis (2013) 1.23
Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS (2006) 1.18
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol (2005) 1.15
Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS (2003) 1.15
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J Med Virol (2005) 1.14
Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol (2004) 1.13
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS (2002) 1.13
HIV incidence and HIV testing behavior in men who have sex with men: using three incidence sources, The Netherlands, 1984-2005. AIDS (2007) 1.13
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. Blood (2011) 1.13
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology (2012) 1.13
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis (2009) 1.12
Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion (2004) 1.12
Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS (2004) 1.11
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS (2009) 1.11
Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis (2011) 1.10
Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS (2004) 1.10
Performance of VIDISCA-454 in feces-suspensions and serum. Viruses (2012) 1.10
Triple HIV-1 infection. N Engl J Med (2005) 1.09